Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.66 |
| ▸ | LMNA | P02545 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | G6PD | P11413 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | MPI | P34949 | 1/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13123060 | 0.89 | ESR1 (0.77) | ESR1ESR2LMNAMEN1MAPT | |
| SCHEMBL2596534 | 0.89 | ESR1 (0.77) | ESR1ESR2LMNAMEN1MAPT | |
| SCHEMBL1048371 | 0.89 | ESR1 (0.77) | ESR1ESR2LMNAMEN1MAPT | |
| SCHEMBL31544736 | 0.89 | ESR1 (0.77) | ESR1ESR2LMNAMEN1MAPT | |
| SCHEMBL14506283 | 0.88 | ESR1 (0.65) | ESR1ESR2LMNAMEN1MAPT | |
| SCHEMBL29635930 | 0.86 | HSD17B10 (0.66) | ESR1ESR2LMNAMEN1MAPT | |
| SCHEMBL5530502 | 0.84 | HSD17B10 (0.67) | ESR1ESR2LMNAMEN1MAPT | |
| SCHEMBL5530501 | 0.84 | HSD17B10 (0.67) | ESR1ESR2LMNAMEN1MAPT | |
| SCHEMBL6883109 | 0.80 | ESR1 (0.73) | ESR1ESR2LMNAMEN1MAPT | |
| SCHEMBL6883111 | 0.80 | ESR1 (0.73) | ESR1ESR2LMNAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1640009-B1 | Estrogenic compounds as antimitotic agents | CHILDRENS MEDICAL CENTER (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1927359-A2 | 2-Methoxyestradiol for the treatment of inflammatory disorders | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-06-04 | — | — | EP | disclosed |
| US-7381848-B2 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-7291610-B2 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7109187-B2 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060183727-A1 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2006-08-17 | — | — | US | disclosed |
| US-7081477-B2 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060079576-A1 | Estrogenic compounds as anti-mitotic agents | D AMATO ROBERT J | 2006-04-13 | — | — | US | disclosed |
| EP-1640009-A1 | Estrogenic compounds as antimitotic agents | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-03-29 | — | — | EP | disclosed |
| US-7012070-B2 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| EP-0713393-B1 | ESTROGENIC COMPOUNDS AS ANTI-ANGIOGENESIS AGENTS | CHILDRENS MEDICAL CENTER (US) | 2005-12-21 | — | — | EP | disclosed |
| US-6930128-B2 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2005-08-16 | — | — | US | disclosed |
| US-6908910-B2 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050020555-A1 | Estrogenic compounds as anti-mitotic agents | D AMATO ROBERT JOHN (US) | 2005-01-27 | — | — | US | disclosed |
| US-6723858-B2 | BREAKING CELL DIVIDING, REPRODUCTION CYCLES | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-6528676-B1 | Estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs; angiogenesis inhibitors | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2003-03-04 | — | — | US | disclosed |
| EP-0713393-A4 | ESTROGENIC COMPOUNDS AS ANTI-MITOTIC AGENTS | CHILDRENS MEDICAL CENTER (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-0713393-A1 | ESTROGENIC COMPOUNDS AS ANTI-MITOTIC AGENTS | The Children's Medical Center Corporation (US) | 1996-05-29 | — | — | EP | disclosed |
| WO-1995004535-A1 | ESTROGENIC COMPOUNDS AS ANTI-MITOTIC AGENTS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020555-A1 | Estrogenic compounds as anti-mitotic agents | NUMA1, CCNB1, CCNB3 | ESR1 47/4885ESR2 50/4885LMNA 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.